Intuitive Surgical, Inc. $ISRG Shares Acquired by Slow Capital Inc.

Slow Capital Inc. grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,146 shares of the medical equipment provider’s stock after acquiring an additional 3,137 shares during the quarter. Intuitive Surgical accounts for approximately 2.7% of Slow Capital Inc.’s investment portfolio, making the stock its 8th largest position. Slow Capital Inc.’s holdings in Intuitive Surgical were worth $23,321,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Tobam grew its position in shares of Intuitive Surgical by 666.7% in the 2nd quarter. Tobam now owns 46 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 40 shares during the last quarter. Kilter Group LLC acquired a new position in Intuitive Surgical in the second quarter valued at approximately $27,000. Princeton Global Asset Management LLC bought a new position in Intuitive Surgical during the second quarter worth $30,000. Riggs Asset Managment Co. Inc. boosted its position in shares of Intuitive Surgical by 84.2% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 70 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 32 shares in the last quarter. Finally, First Command Advisory Services Inc. grew its stake in Intuitive Surgical by 3,750.0% in the second quarter. First Command Advisory Services Inc. now owns 77 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 75 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, EVP Myriam Curet sold 7,562 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $548.43, for a total transaction of $4,147,227.66. Following the sale, the executive vice president owned 353 shares in the company, valued at approximately $193,595.79. This trade represents a 95.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mark Brosius sold 4,500 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $547.36, for a total value of $2,463,120.00. Following the completion of the transaction, the senior vice president owned 907 shares of the company’s stock, valued at $496,455.52. The trade was a 83.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 114,007 shares of company stock valued at $63,533,844. Company insiders own 0.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on ISRG. Robert W. Baird set a $655.00 price target on Intuitive Surgical in a research report on Wednesday, October 22nd. Truist Financial upped their price objective on Intuitive Surgical from $620.00 to $650.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Wells Fargo & Company lifted their target price on shares of Intuitive Surgical from $600.00 to $654.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Argus increased their price target on shares of Intuitive Surgical from $600.00 to $630.00 in a report on Monday, October 27th. Finally, Citigroup cut Intuitive Surgical from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $650.00 to $635.00 in a research report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $622.17.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $535.00 on Tuesday. The firm has a 50-day moving average of $565.50 and a 200 day moving average of $511.79. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $616.00. The stock has a market cap of $191.79 billion, a P/E ratio of 70.77, a price-to-earnings-growth ratio of 4.35 and a beta of 1.67.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, October 21st. The medical equipment provider reported $2.40 EPS for the quarter, beating the consensus estimate of $1.99 by $0.41. The company had revenue of $2.51 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.Intuitive Surgical’s revenue was up 22.9% compared to the same quarter last year. During the same period last year, the firm posted $1.84 earnings per share. Research analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.